Moldova is now a new player in the pharmaceutical market. Despite its short history in clinical trials, Moldova is developing quite successfully in this area.Moldova has a fairly robust pharmacovigilance system based on European principles, which guarantees reliability and compliance with all safety requirements. The rapid growth is also due to a developed and innovative pharmaceutical system.
The pharmaceutical industry in Moldova can also guarantee a high speed of review procedures. Today, the standard review procedure in Moldova takes 30 days for phases I-III, while the accelerated procedure takes only 10 working days, which is the fastest timeframe among European countries, as well as one of the most reliable.
Since 2016, Moldova has met all the requirements and standards set by the European Pharmacology, which makes the review procedure similar to the EU system. The review depends on the regulatory body, the Medicines Agency, and also on the Ethics Committee. All clinical trial sites must be accredited and comply with national and GCP (Good Clinical Practice) standards.
CLINICAL DEVELOPMENT SOLUTIONS OVERVIEW
CLINICAL TRIALS IN MOLDOVA
Moldova is now a new player in the pharmaceutical market. Despite its short history in clinical trials, Moldova is developing quite successfully in this area.Moldova has a fairly robust pharmacovigilance system based on European principles, which guarantees reliability and compliance with all safety requirements. The rapid growth is also due to a developed and innovative pharmaceutical system.
The pharmaceutical industry in Moldova can also guarantee a high speed of review procedures. Today, the standard review procedure in Moldova takes 30 days for phases I-III, while the accelerated procedure takes only 10 working days, which is the fastest timeframe among European countries, as well as one of the most reliable.
Since 2016, Moldova has met all the requirements and standards set by the European Pharmacology, which makes the review procedure similar to the EU system. The review depends on the regulatory body, the Medicines Agency, and also on the Ethics Committee. All clinical trial sites must be accredited and comply with national and GCP (Good Clinical Practice) standards.